Market closed·Syncing…
Market closed · Close · 18 Nov

Aarti Drugs Limited AARTIDRUGSshare price and chart

Aarti Drugs closed at ₹505.75 on 18 November 2026, up 0.59% on the day. The 52-week range is ₹318.95 to ₹527.50.

₹505.75The price one share last traded at, in rupees.+0.59% · ₹2.97
52-wk low ₹31990% up the rangeThe highest and lowest price the share has traded at in the past year, and where today's price sits between the two.high ₹528

Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.

Loading prices…

Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.

Test a strategy on AARTIDRUGS

Real prices, every charge counted. Pick one or write your own.
What Aarti Drugs Limited does
A short, human-reviewed summary of the business, written from public sources. Background, not analysis, and not updated intraday.
business summary

Aarti Drugs makes active pharmaceutical ingredients, which are 89% of its turnover, along with speciality chemicals and intermediates. It sells to drug formulation companies, speciality chemical makers and dye and pigment makers worldwide, and exports are 38% of turnover. It runs 13 plants.

1
1Sector

Pharmaceuticals & Biotechnology

2
2What it sells

Active pharmaceutical ingredients, speciality chemicals, intermediates

3
3Who buys it

Drug formulation companies, speciality chemical makers, dye and pigment makers

Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.

EOD 18 Nov
RSI (14) · 30 oversold, 70 overboughtA score from 0 to 100 showing how strong recent up days were against recent down days.
68.5Neutral
0 oversold3070overbought 100
Delivery · bought to hold vs churnOf all the shares traded in a day, the share that actually changed hands and went into someone's demat account, rather than being bought and sold the same day.
31.5%Near average
today 31.5%20d avg 35.7%

The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.

vs 50 DMAHow far today's close is above or below the average closing price of the last 50 trading days. It shows the medium-term trend.+16.5%vs 200 DMAHow far today's close is above or below the average closing price of the last 200 trading days, about ten months. It is the most watched line for the long-term trend.+27.9%1 monthHow much the share price has changed over the period.+26.7%3 monthsHow much the share price has changed over the period.+22.5%1 yearHow much the share price has changed over the period.+6.5%Vol 30dHow much the share has actually been moving day to day, stated as a yearly percentage. 30% means it swung roughly 30% a year at that pace.55%

Returns and valuationWhat the market pays for this company and how well the business uses its money.

Books to 30 Sept 2026
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.₹4,616 Cr18 NovP/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.20.2xlast 4 quarters, to Sept 2026Return on equityHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.13.4%full year FY26Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.2.75xbooks of Sept 2026Return on capitalHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.11.9%full year FY26EV / EBITDAWhat it would cost to buy the whole company, against the cash profit its business makes in a year. It is a P/E that ignores how the company is financed.16.8xDividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.0.40%last 12 monthsDebt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.37xbooks of Sept 2026FCF marginOf every ₹100 of sales, how much cash was left after running the business and paying for new assets.3.1%year to Mar 2026

Against its sectorWhere this company ranks among similar companies on each measure.

Pharmaceuticals · 141 peers · medians
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.20.19vs 32.89 median
Cheapest: WALPAR 7.92Priciest: COHANCE 507.11
Net marginOf every ₹100 of sales, how much is left as profit after all costs, interest and tax.8.02%vs 10.23% median
Lowest: MEDIORG -86.72%Highest: SHUKRAPHAR 38.89%
Revenue growthHow much sales grew in the latest quarter against the same quarter a year earlier.26.57%vs 20.87% median
Lowest: NECLIFE -99.78%Highest: SHUKRAPHAR 652.15%

What the numbers sayShort plain statements about this company's latest figures.

Written by fixed rules

Latest quarterIn the quarter to September 2026 (results filed 3 Nov 2026), sales rose 26.6% from a year earlier to ₹826 cr and profit rose 83.3% to ₹82.8 cr.

Going well
  • Cash from operations was at least the reported profit in each of FY24, FY25, FY26.

Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.

Share price reaction to resultsWhat the share price did around each recent quarterly result.

Over the last 18 results, the share rose on 7 and fell on 11, and moved by 3% or more on 8.

+19%
-19%
Q4 FY22Q4 FY23Q4 FY24Q2 FY26Q2 FY27

Q2 FY27: results filed 3 Nov 2026. The share went from its close on 2 Nov 2026 to its close on 4 Nov 2026 +0.44%.

Dividend historyCash the company has paid per share, year by year.

₹400 / year
Paid 10 of 11 yrs
on ₹1 lakh at today's price · 0.40% yield · ₹2/share
What each year paid, on ₹1 lakh
49
49
49
593
198
198
198
198
395
17
18
19
20
21
22
23
24
25
26*
* 2026 so far - more may still be declared this year

2026 has paid ₹2.00 per share, about ₹395 on ₹1 lakh at today's price. It skipped 1 of the last 11 years. Earlier years are restated to today's share count, so a bonus or split never reads as a dividend cut. Dividends are at the company's discretion and can be cut or skipped.

What it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.

Price only, before dividends
+12.8%a year, over 10 years
1 yr
+10.6%
3 yr
+1.9%
5 yr
-1.3%
10 yr
+12.8%

Held for 10 years this compounded at +12.8% a year. The last twelve months were up +10.6%. Price only, before dividends.

Shareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.

Who owns it
54.07%promoter holding, as of 2026-09-30-6.0 pts since 2021
Promoter share since listing
2021-0954.07% now, drawn to its own range2026-09
Who owns it todayas of Sep 26
54.1%
33.4%
Promoter54.1%Foreign (FII)2.3%Domestic (DII)10.2%Public & others33.4%
Who is buying, who is leavingJun 25 to Sep 26
Promoter54.1%-1.1 pts
Foreign (FII)2.3%steady
Domestic (DII)10.2%+0.3 pts

Each line is that holder's share of all shares over the last 6 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.

The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.

Promoter pledgeThe share of promoters' holdings given to lenders as security for a loan.2.51%of promoter shares, as at 2026-09-30

Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.

Last 6 months
General Updates15-Nov-2026

Aarti Drugs Limited has informed the Exchange about sad demise of Promoter and Chairman Emeritus of the Company

Analysts/Institutional Investor Meet/Con. Call Updates10-Nov-2026

Aarti Drugs Limited has informed the Exchange about Transcript

Updates06-Nov-2026

Aarti Drugs Limited has informed the Exchange regarding 'Inspection by USFDA of formulation facility of subsidiary Company, Pinnacle Life Science Private Limited'.

Copy of Newspaper Publication05-Nov-2026

Aarti Drugs Limited has informed the Exchange about Copy of Newspaper Publication

Analysts/Institutional Investor Meet/Con. Call Updates04-Nov-2026

Aarti Drugs Limited has informed the Exchange about Link of Audio Recording of Conference Call for Investor and Analysts

Investor Presentation03-Nov-2026

Aarti Drugs Limited has informed the Exchange about Investor Presentation

Press Release03-Nov-2026

Aarti Drugs Limited has informed the Exchange regarding a press release dated November 03, 2026, titled "Q2&H1FY27 Business and Financial Performance".

Outcome of Board Meeting03-Nov-2026

Aarti Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

Analysts/Institutional Investor Meet/Con. Call Updates28-Oct-2026

Aarti Drugs Limited has informed the Exchange about Q2 H2 FY27 Earning Call Conference Intimation

General Updates08-Oct-2026

Aarti Drugs Limited has informed the Exchange about Crisil ESG Rating

Certificate under SEBI (Depositories and Participants) Regulations, 201807-Oct-2026

Aarti Drugs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

General Updates01-Oct-2026

Aarti Drugs Limited has informed the Exchange about General Updates

Resignation of Director/KMP/SMP30-Sep-2026

Aarti Drugs Limited has informed the Exchange about Resignation of Director/KMP/SMP

Change in Management30-Sep-2026

Aarti Drugs Limited has informed the Exchange about change in Management

Trading Window29-Sep-2026

Aarti Drugs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Backtest idea · AARTIDRUGSMACD momentum

Momentum turning up, only while the long trend is up.

BuyMACD crosses above signal, price above 200-day SMA
SellMACD crosses back below
Real prices · every charge countedRun on AARTIDRUGS
Backtest idea · AARTIDRUGSLower band bounce

Buys a stretch below the usual range, sells on the way back.

BuyCloses below the lower Bollinger band
SellBack at the middle band, or 15 days
Real prices · every charge countedRun on AARTIDRUGS
Backtest idea · AARTIDRUGSSupertrend rider

Stays in while the trend line says up, out when it flips.

BuySupertrend turns up
SellSupertrend turns down
Real prices · every charge countedRun on AARTIDRUGS
Your own ideaWrite a rule for AARTIDRUGS in plain English“Buy AARTIDRUGS when …”
Start writing
Buy the dip on AARTIDRUGSBuy when RSI(14) drops below 30
52-week high breakout on AARTIDRUGSBuy when closes at a 52-week high
Golden cross on AARTIDRUGSBuy when 50-day EMA crosses above 200-day
Stochastic oversold on AARTIDRUGSBuy when stochastic %K drops below 20
Pullback in an uptrend on AARTIDRUGSBuy when RSI(14) below 40, price above 200-day EMA

Key ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.

Against its sector
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.
₹4,616 cr
Larger than 58% of 141 peers
sector middle ₹2,247 cr
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.
20.2x
Lower than 77% of 118 peers
sector middle 32.9x
Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.
2.8x
Lower than 63% of 125 peers
sector middle 3.6x
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.
13.4%
Around the middle of 109 peers
sector middle 12.3%
FY23 13.2%FY26 13.4%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.
11.9%
Lower than 60% of 124 peers
sector middle 15.0%
FY23 14.3%FY26 11.9%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.
0.37
Higher than 70% of 125 peers
sector middle 0.19
FY23 0.51FY26 0.37
Dividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
0.4%
Higher than 71% of 141 peers
sector middle 0.1%
Sales growthHow much sales grew in the latest quarter against the same quarter a year earlier.
+26.6%
Higher than 61% of 130 peers
sector middle +20.9%
FY23 6.3%FY26 7.5%

Peers are the listed companies in the exchange's own industry group: Pharmaceuticals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

Revenue and profit, year by yearSales and net profit by financial year or by quarter.

Sales and net profit
FY22FY23FY24FY25FY26
SalesNet profitfell vs last yearEach on its own scale · hover a bar for its figures
Op. marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.12.1%FY26Profit YoYHow much net profit grew in the latest quarter against the same quarter a year earlier.+83.3%latest quarterSalesMoney earned from selling the company's goods and services, before any costs. Also called revenue.₹2,565 CrFY26Net profitWhat is left for shareholders after all costs, interest and tax.₹195 CrFY26

Where every ₹100 of sales goesHow each ₹100 the company sold was spent, and how much stayed as profit.

FY26

In FY26, of every ₹100 of sales it kept ₹7.6 as profit.

Where it wentPer ₹100 of sales
Running costs₹87.9Depreciation₹2.6Interest₹1.3Tax₹0.6Profit₹7.6
Profit per ₹100, year by year
FY22FY26

How fast it has grownCompound growth a year in sales and profit, over 3 and 5 financial years, beside the latest quarter.

Compounded a year
3 years5 yearsLatest qtr
Sales▼ 1.0%-+26.6%
Profit+7.3%-+83.3%
3 and 5 years are compounded a year across full financial years. The latest quarter is against the same quarter a year earlier.

Cash flowProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.

Where the cash went

In FY26 cash rose by ₹3 Cr, after ₹173 Cr spent on plant and equipment.

FY26Cash in or out
Running the business+₹254 Cr
Investing-₹173 Cr
Lenders and shareholders-₹77 Cr
Net change in cash+₹3 Cr
Operating cash per ₹100 of profit
₹81FY23₹209FY24₹145FY25₹130FY26
₹100 or more means the reported profit arrived as cash.

Health check, year by yearMargins, returns and debt for each financial year, so you can see the direction.

MeasureFY23FY24FY25FY26
Sales growthSales in this financial year against the previous one.6.3%-4.4%-5.6%7.5%
Operating marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.11.1%12.5%12.0%12.1%
Net marginOf every ₹100 of sales in the year, how much was left as profit after everything.6.0%6.8%7.0%7.6%
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.13.2%13.9%12.7%13.4%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.14.3%14.8%12.9%11.9%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.51x0.44x0.45x0.37x
Interest coverHow many times the company's profit before interest could pay its interest bill.7.4x8.0x6.9x7.3x

Each row against this company's own usual level: green better, red worse, grey close to it.

Backtest idea · AARTIDRUGSStochastic oversold

Buys when the close sits near the bottom of its recent range.

BuyStochastic %K drops below 20
Sell8% profit, or after 15 days
Real prices · every charge countedRun on AARTIDRUGS
Backtest idea · AARTIDRUGSPullback in an uptrend

Buys a pause inside a rising trend.

BuyRSI(14) below 40, price above 200-day EMA
Sell8% profit, or after 30 days
Real prices · every charge countedRun on AARTIDRUGS
Backtest idea · AARTIDRUGSBuy the dip

Buys after a sharp fall, betting on a bounce.

BuyRSI(14) drops below 30
Sell10% profit, or after 20 days
Real prices · every charge countedRun on AARTIDRUGS
Backtest idea · AARTIDRUGS52-week high breakout

Buys strength, when the price makes a new one-year high.

BuyCloses at a 52-week high
Sell8% stop loss
Real prices · every charge countedRun on AARTIDRUGS
Backtest idea · AARTIDRUGSGolden cross

Follows the long trend: in when the fast average crosses above the slow one.

Buy50-day EMA crosses above 200-day
SellWhen it crosses back below
Real prices · every charge countedRun on AARTIDRUGS
MACD momentum on AARTIDRUGSBuy when MACD crosses above signal, price above 200-day SMA
Lower band bounce on AARTIDRUGSBuy when closes below the lower Bollinger band
Supertrend rider on AARTIDRUGSBuy when supertrend turns up
Buy the dip on AARTIDRUGSBuy when RSI(14) drops below 30
52-week high breakout on AARTIDRUGSBuy when closes at a 52-week high

Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.

Pharmaceuticals
CompanyWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.How much operating profit the company made on all the money in the business, whether it came from owners or lenders.Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.Of every ₹100 of sales, how much is left as profit after all costs, interest and tax.How much sales grew in the latest quarter against the same quarter a year earlier.The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
SUNPHARMA
Sun Pharmaceutical Industries Limited
4.49 L cr41.0x5.0x14.7%19.1%0.0317.8%+11.9%0.85%
DIVISLAB
Divi's Laboratories Limited
2.93 L cr87.2x16.3x16.2%21.5%0.0027.6%+35.4%0.27%
TORNTPHARM
Torrent Pharmaceuticals Limited
1.75 L cr77.9x9.6x17.0%15.2%0.7612.1%+50.8%0.82%
LAURUSLABS
Laurus Labs Limited
1.25 L cr93.6x20.7x17.7%17.9%0.4017.0%+33.4%0.09%
ZYDUSLIFE
Zydus Lifesciences Limited
1.20 L cr28.9x4.3x18.3%19.9%0.4414.1%+29.2%0.08%
DRREDDY
Dr. Reddy's Laboratories Limited
1.17 L cr41.6x3.0x11.5%13.9%0.158.3%-1.5%0.57%
CIPLA
Cipla Limited
1.14 L cr39.5x3.2x11.7%16.0%0.0110.1%-2.4%0.92%
MANKIND
Mankind Pharma Limited
1.08 L cr48.3x6.2x12.4%12.9%0.3014.7%+17.3%0.00%
AUROPHARMA
Aurobindo Pharma Limited
1.03 L cr26.1x2.6x9.9%12.8%0.2110.8%+23.9%0.39%
LUPIN
Lupin Limited
90,173 cr17.3x3.8x26.9%28.8%0.2317.0%+11.1%0.91%
GLENMARK
Glenmark Pharmaceuticals Limited
74,679 cr51.5x6.7x14.1%20.4%0.089.2%-31.3%0.09%
ALKEM
Alkem Laboratories Limited
62,443 cr30.2x4.2x17.6%20.6%0.1213.4%+13.8%1.01%
BIOCON
Biocon Limited
58,987 cr215.4x1.7x1.1%3.0%0.411.9%+2.2%0.14%
ABBOTINDIA
Abbott India Limited
54,122 cr32.7x----23.0%+11.0%2.58%
GLAND
Gland Pharma Limited
53,307 cr43.1x5.0x10.5%15.0%0.0217.5%+23.3%0.62%
IPCALAB
IPCA Laboratories Limited
47,039 cr33.5x5.4x13.2%16.6%0.0614.2%+13.8%0.32%
GLAXO
GlaxoSmithKline Pharmaceuticals Limited
44,693 cr39.5x23.8x48.9%66.5%0.0027.6%+20.8%2.16%
EMCURE
Emcure Pharmaceuticals Limited
44,294 cr40.5x8.3x19.6%24.8%0.2710.7%+24.3%0.15%
AJANTPHARM
Ajanta Pharma Limited
40,909 cr32.4x8.4x25.4%32.7%0.0220.3%+32.5%0.98%
SAILIFE
Sai Life Sciences Limited
37,978 cr100.5x14.1x15.1%20.9%0.1715.9%+22.5%0.00%
WOCKPHARMA
Wockhardt Limited
32,931 cr80.3x6.4x4.0%6.5%0.3910.8%+23.9%0.00%
ACUTAAS
Acutaas Chemicals Limited
32,677 cr74.4x17.6x23.5%31.7%0.0027.5%+42.7%0.06%
PPLPHARMA
Piramal Pharma Limited
31,813 cr-3.9x-4.0%0.8%0.69-2.1%+28.1%0.00%
NEULANDLAB
Neuland Laboratories Limited
27,527 cr60.8x13.6x21.4%27.5%0.1719.6%-12.6%0.16%
RUBICON
Rubicon Research Limited
27,450 cr84.1x19.4x19.1%23.4%0.2815.5%+39.9%0.09%
APLLTD
Alembic Pharmaceuticals Limited
20,528 cr24.3x3.5x12.4%11.7%0.259.9%+36.3%1.15%
GRANULES
Granules India Limited
19,762 cr27.6x3.0x13.5%15.7%0.0912.1%+20.3%0.22%
ERIS
Eris Lifesciences Limited
18,530 cr26.0x4.5x18.1%13.9%0.5821.6%+12.6%0.54%
ONESOURCE
Onesource Specialty Pharma Limited
18,189 cr-3.1x-1.3%0.4%0.25-0.1%+37.4%0.00%
SHILPAMED
Shilpa Medicare Limited
17,902 cr53.6x6.5x9.8%11.4%0.2418.1%+43.0%0.07%
ALIVUS
Alivus Life Sciences Limited
17,737 cr26.5x4.9x18.4%24.6%0.0024.9%+16.0%0.35%
PFIZER
Pfizer Limited
17,575 cr20.4x4.0x17.2%23.4%0.0032.4%+13.2%1.95%
COHANCE
Cohance Lifesciences Limited
17,462 cr507.1x4.5x5.1%8.0%0.06-0.3%-14.2%0.00%
NATCOPHARM
Natco Pharma Limited
16,098 cr17.7x1.6x16.9%17.1%0.1126.9%-29.0%0.70%
CAPLIPOINT
Caplin Point Laboratories Limited
15,851 cr23.0x4.1x19.9%24.7%0.0029.4%+17.9%0.38%
ASTRAZEN
AstraZeneca Pharma India Limited
15,109 cr85.0x17.2x22.8%31.2%0.006.8%+30.4%0.60%
JUBLPHARMA
Jubilant Pharmova Limited
14,870 cr56.2x2.1x6.0%8.7%0.542.9%+20.5%0.54%
CORONA
CORONA Remedies Limited
13,799 cr66.7x17.1x24.8%27.8%0.1213.3%+22.2%0.44%
MARKSANS
Marksans Pharma Limited
13,349 cr23.8x4.0x25.4%35.1%0.0116.7%+30.5%0.31%
AARTIDRUGS
Aarti Drugs Limited
4,616 cr20.2x2.8x13.4%11.9%0.378.0%+26.6%0.40%

Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.

Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.

Month by month
YearJanFebMarAprMayJunJulAugSepOctNovDecYear
2026
-7.4
-3.7
-12.9
+17.7
+1.1
-0.7
+11.9
-2.6
+4.7
+1.0
+14.6
·
+21.2%
11m
2025
-11.9
-13.3
-3.1
+2.6
+27.2
+3.2
+10.6
-7.3
+3.6
+0.9
-13.5
-3.1
-10.6%
2024
+7.7
-5.5
-12.7
+16.2
-5.5
+5.8
+1.1
+14.2
-11.9
-5.7
-4.8
-0.1
-5.9%
2023
-12.8
-8.7
-7.8
+24.6
+3.8
+6.5
+27.8
-3.7
-5.2
-13.5
+3.9
+0.3
+6.3%
2022
-7.6
-9.5
-5.8
+7.5
-7.7
-5.1
+3.7
+3.0
+8.6
+2.3
-5.5
+1.6
-15.6%
2021
-4.5
-6.3
+10.1
+2.3
+2.5
-2.7
-5.7
-7.7
-1.4
-3.6
-13.5
+7.5
-22.7%
2020
+6.1
+12.8
-27.5
+42.4
+35.9
+30.7
+37.0
+55.9
+13.8
-11.7
+5.0
-1.4
+387.0%
2019
+2.1
+0.1
+8.1
-2.7
-8.2
-6.8
-12.9
+0.7
-2.5
+18.5
-3.3
+11.4
+0.5%
2018
-2.5
-3.9
-15.7
+13.4
-9.4
+6.6
+1.0
-0.8
-1.0
+7.7
-6.5
+4.3
-10.1%
2017
+2.3
-3.1
-4.1
-1.4
-14.8
+8.3
+8.0
-8.8
+1.1
+3.1
+2.7
+16.1
+5.9%
Monthly movebelow -10%-10 to -5-5 to -2-2 to 00 to +2+2 to +5+5 to +10above +10%month in progress

Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.

Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.

DatePartySideQuantityPriceValue
2026-11-09MICROCURVES TRADING PRIVATE LIMITED · bulkSELL13,52,619₹500.65₹67.72 Cr
2026-11-09MICROCURVES TRADING PRIVATE LIMITED · bulkBUY13,52,619₹500.23₹67.66 Cr
2026-11-09QE SECURITIES LLP · bulkSELL9,00,829₹502.28₹45.25 Cr
2026-11-09QE SECURITIES LLP · bulkBUY8,85,686₹497.86₹44.09 Cr
2026-11-09ALPHAGREP SECURITIES PRIVATE LIMITED · bulkBUY8,68,877₹499.83₹43.43 Cr
2026-11-09ALPHAGREP SECURITIES PRIVATE LIMITED · bulkSELL8,68,877₹500.60₹43.50 Cr
2026-11-09JUNOMONETA FINSOL PRIVATE LIMITED · bulkBUY7,44,831₹500.07₹37.25 Cr
2026-11-09JUNOMONETA FINSOL PRIVATE LIMITED · bulkSELL7,42,922₹500.38₹37.17 Cr

The last two years of the company's filings to the exchange, grouped by the exchange's own categories. Each opens the original document.

Read enough? Test AARTIDRUGS. “Buy AARTIDRUGS when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.

Run it free